We are pleased to announce that the U.S. FDA has granted rare pediatric disease and #orphandrug designations to our lead program, EN-374, for the treatment of X-linked chronic granulomatous disease (#XCGD). We plan to submit an IND for EN-374 in the first half of this year. Read

We recently served lunch & connected with patients and families at the AstraZeneca Hope Lodge. The Hope Lodge serves as a "home away from home" for patients & caregivers while going through cancer treatment. We were honored to spend time at the lodge and be a part of their

Rare diseases are more common than you realize, and their impact on patients & families is #MoreThanYouCanImagine. Yesterday, 300+ Boston Seaport biotech members walked for the 300 million people whose lives have been altered by a rare disease and for better, equitable care.

At Ensoma, we are committed to a better future for patients, each other, and the community. On #EmployeeAppreciationDay, we are grateful for our incredible team's work each day to push beyond today’s possible in genomic medicines, and the open, collaborative and driven

We recently got together at our annual winter party to celebrate each other and what we are building here at Ensoma. Check out some highlights of our memorable night! 📸

Ensoma VP of Clinical Research & Development Drew Dietz looks forward to leading the Cell & Gene Therapy roundtable during the #CMO360Summit next week! Check out the full agenda for this exciting 2-day event: cmosummit360.com

We're thrilled to share we have been shortlisted for the 2025 Citeline Most Successful Early Stage Research award, recognizing a project that met or surpassed its objectives on a range of KPI's. Our compelling body of early-phase research across 3 key programs targeting genetic,

Our Chief Corporate Development & Business Officer, Jon Garen, is headed to Alliance for Regenerative Medicine (ARM)'s #CGMed25 next week. Join us Wednesday, April 16 at 9:45am local time in Salone dei Cavalieri, Section 2 for the latest on Ensoma's progress as we prepare to enter the clinic later this year.

Last year, we began a concerted effort to increase our environmental responsibility and sustainability efforts in our labs at Ensoma. This week, we are celebrating #EarthDay and #WorldLabDay by thanking our partner, Polycarbin, for giving us the tools to reduce waste and

Today, we celebrate #NationalDNADay to honor the 1953 discovery of DNA's double helix and the 2003 completion of the Human Genome Project. Since then, research has harnessed the power of DNA to make genetic medicines. Ensoma is pioneering a unique system to deliver #DNA to the

We're pleased to announce we will present preclinical data & manufacturing advancements at #ASGCT2025 next month. These presentations will highlight key programs that leverage our in vivo HSC engineering platform. With this exciting progress, we remain on track to initiate a

Today marks the end of #WorldPIWeek2025. 6 million people worldwide live with a #PrimaryImmunodeficiency, yet 70-90% of people remain undiagnosed. We are proud to be part of the global effort to raise awareness of PIs, including Chronic Granulomatous Disease (CGD), and advocate

We're pleased to announce #FDA clearance of our Investigational New Drug (IND) application for Ensoma's lead program, EN-374, in X-linked chronic granulomatous disease (X-CGD), a rare, severe genetic immune deficiency that leaves people vulnerable to life-threatening infections.

Ensoma is on the ground for #ASGCT2025! Our team is enjoying connecting with peers, sharing our preclinical data and learning more about other new innovations in the cell & gene therapy space. Find details on Ensoma’s poster presentations here. ensoma.com/press-release/…

As #ASGCT2025 comes to a close, we're grateful for a productive week. Thanks to those who stopped by our poster sessions presented by Chirayu Chokshi, Sravya Kattula, Patrick Au and Chapman Wright. Thank you to ASGCT for another energizing meeting.

CSO Rob Peters will join the cell & gene community at the In Vivo Cell Engineering & #GeneEditing Summit today! Join Rob for his presentation during the Analyzing Market Trends & Scientific Advancements to Shape the Future of In Vivo Cell & Gene Therapies session. Details:

At Ensoma, the growth & development of our team members is a priority. We recently kicked off Biotech 101, an internal series where leaders at Ensoma share their expertise + experience with our team to broaden their industry knowledge. We started with a deep dive into industry

The world can't wait for breakthrough therapies and medical innovations. That's why events like #BIO2025 are a cornerstone of our industry, and we value opportunities to engage with the #geneengineering community. Connect with CEO Jim Burns & Director of Corporate Development

People with #SickleCell often endure a difficult and agonizing journey, facing severe complications including debilitating pain crises, anemia, infertility, increased risk of infections, stroke and organ damage. SCD affects ~100,000 adults and children in the U.S. Today on